^
    2d
    Thyroid-originated pleomorphic rhabdomyosarcoma with novel TP 53 intron frameshift mutation: a case report and literature review. (PubMed, World J Surg Oncol)
    Under specific circumstances, CNB can provide an effective diagnostic approach for thyroid tumors. Moreover, in this case, we identified a novel TP53 intronic mutation that may drive the development of thyroid PRMS.
    Journal
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NKX2-1 (NK2 Homeobox 1) • MYOD1 (Myogenic Differentiation 1)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • RET mutation • RET rearrangement
    2d
    DP19 Epithelioid sarcoma of the hand in a young adult. (PubMed, Br J Dermatol)
    Epithelioid sarcoma carries a high risk of recurrence or metastasis. Long-term follow-up is essential due to the tumour's propensity for recurrence and metastatic spread.
    Journal
    |
    CD163 (CD163 Molecule) • VIM (Vimentin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    2d
    DP20 Soft-tissue perineurioma presenting as a painless nasal papule. (PubMed, Br J Dermatol)
    S100, SOX10, neurofilament and desmin are typically negative. While perineuriomas behave in a benign fashion, complete surgical excision is recommended.
    Journal
    |
    CD34 (CD34 molecule) • SOX10 (SRY-Box 10) • MME (Membrane Metalloendopeptidase) • MLANA (Melan-A) • F13A1 (Coagulation Factor XIII A Chain) • SLC2A1 (Solute Carrier Family 2 Member 1)
    3d
    Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01） (clinicaltrials.gov)
    P2, N=30, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Apr 2023 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib)
    3d
    Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01) (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase classification: P2 --> P=N/A | N=28 --> 50 | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    3d
    MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov)
    P3, N=603, Active, not recruiting, Institut National de la Santé Et de la Recherche Médicale, France | Trial completion date: Oct 2025 --> Jan 2026
    Trial completion date • IO biomarker
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Imfinzi (durvalumab) • lapatinib • Zykadia (ceritinib) • Tasigna (nilotinib) • Lytgobi (futibatinib) • Tabrecta (capmatinib) • Daurismo (glasdegib)
    3d
    Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors. (PubMed, J Immunother Cancer)
    These data identify tolerated dose levels for a novel, intravenously delivered STING agonist compound that results in on-target effects in systemic and intratumoral immune responses in dogs with solid tumors.
    Journal
    |
    IL6 (Interleukin 6) • STING (stimulator of interferon response cGAMP interactor 1)
    3d
    Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02） (clinicaltrials.gov)
    P2, N=30, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting --> Completed
    Trial completion
    |
    AiTan (rivoceranib)
    3d
    Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03) (clinicaltrials.gov)
    P2, N=52, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting --> Completed | N=100 --> 52 | Trial completion date: Dec 2026 --> Dec 2024 | Trial primary completion date: Apr 2026 --> Dec 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    AiRuiYi (fluzoparib)
    3d
    Unusual presentation of dermatofibrosarcoma protuberans of the thigh: a case report. (PubMed, Ann Med Surg (Lond))
    Even in uncommon locations like the thigh, DFSP should be considered in cases of chronic, atypical skin lesions. For the best results, interdisciplinary care, extensive excision, and early diagnosis are essential.
    Journal
    |
    CD34 (CD34 molecule)
    3d
    The Immune Landscape of Canine Soft Tissue Sarcomas as a Model for Human Soft Tissue Sarcomas. (PubMed, Cancers (Basel))
    Gene expression profiling demonstrated similarities between canine STS and human undifferentiated pleomorphic sarcomas, with MYC dysregulation emerging as a poor prognostic indicator for dogs. The comparative analysis between the human and canine STS microenvironment offers a valuable insight into the clinical behavior and immune landscape of canine STS, underscoring its potential as a relevant preclinical model for the translation and development of future immunotherapies.
    Journal • IO biomarker
    |
    FOXP3 (Forkhead Box P3) • MSR1 (Macrophage Scavenger Receptor 1)
    3d
    Challenges and Progress for Treatment of Malignant Peripheral Nerve Sheath Tumors in the Context of Recent Successes for Sarcoma Therapy. (PubMed, Cancers (Basel))
    The development of new agents for MPNST treatment has shifted away from solely targeting RAS pathway gene products to stimulating the immune system and manipulating other MPNST driver mutations such as CDKN2A/B, SUZ12, EED, and TP53. This review presents recent advances in the treatment of sarcomas and the future of drug development targeting MPNSTs.
    Review • Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
    |
    TP53 mutation